News
News

The latest updates from AFAR.

Richard W. Besdine, MD, on Preventing and Treating Stroke

Jun 22
2012

Richard W. Besdine, MD, on Preventing and Treating Stroke

Although it is the third most common cause of death in America, stroke is commonly misunderstood. In his latest blog post, AFAR Medical Officer Richard W. Besdine, MD, dispels common myths and shares valuable but little-known information about stroke risk, prevention—both through lifestyle and medication—and treatment. Dr. Besdine also discusses conditions, atrial fibrillation and hypertension, that increase the risk of stroke but are often undertreated in the elderly. This is the ninth post in Dr. Besdine's series on health care and aging on the AOL Healthy Living site. Read all of his articles here.


View MoreREAD MORE


2012 AFAR Grantee Conference

Jun 11
2012

2012 AFAR Grantee Conference

Recent AFAR grantees gathered from June 3-5 in Santa Barbara, CA, to share their research and meet other scientists in the field of aging research at AFAR’s 25th annual grantee conference. Jan van Deursen, PhD, leader of a study on senescent cells and diseases of aging at Mayo Clinic, delivered the keynote address on his groundbreaking work. Recipients of the Julie Martin Mid-Career and Breakthroughs in Gerontology (BIG) Awards also presented their AFAR-funded projects, which spanned a broad range of topics in aging research. A highlight of the meeting was the small group poster session, which gave grantees…


View MoreREAD MORE


Grantees in the News: Randall Bateman, MD, and Alzheimer’s Therapy Trials

Jun 07
2012

Grantees in the News: Randall Bateman, MD, and Alzheimer’s Therapy Trials

A June 7 story in The New York Times Magazine featured Randall Bateman, MD, and his work in the Dominantly Inherited Alzheimer Network (DIAN). DIAN is an international study of volunteers who have a rare form of inherited Alzheimer’s disease (AD) to analyze the progression of AD in the brain in the years before AD is typically diagnosed. Based on the changes they have observed in these participants’ brains, Dr. Bateman and DIAN researchers have determined that the best time to begin treating AD is likely to be fifteen years before symptoms are usually identified. Dr. Bateman is…


View MoreREAD MORE




BACK TO TOPBACK TO TOP